plasminogen


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

plasminogen

 [plaz-min´o-jen]
the inactive precursor of plasmin, occurring in plasma and converted to plasmin by the action of urokinase; called also profibrinolysin.

plas·min·o·gen

(plaz-min'ō-jen), [MIM*173350]
A precursor of plasmin. There is an autosomal dominant deficiency of plasminogen [MIM*173350] that may promote thrombosis.
See: plasmin.

plasminogen

(plăz-mĭn′ə-jən)
n.
The inactive precursor to plasmin that is found in body fluids and blood plasma.

plasminogen

An 88 kD single-stranded plasmin proenzyme present in the circulation which is converted to plasmin by cleavage of the Arg-Val bond; it is synthesized in the liver, produced or stored in eosinophils and forms complexes with fibrinogen and fibrin; during coagulation, large amounts of plasminogen are integrated in the fibrin clot ↑ in DVT, infection, inflammation, CA, MI, OCs, pregnancy, physical stress, surgery, trauma ↓ in Cirrhosis, other liver disease, DIC, fibrinolysis, hyaline membrane disease–RDS of newborn, renal disease, post-surgery–eg, CABG, thrombosis Normal 2.5-5.2 U/mL–US: 20 mg/dL

plas·min·o·gen

(plaz-min'ŏ-jen)
A precursor of plasmin; an autosomal dominant deficiency of plasminogen that may promote thrombosis.
See also: plasmin

plasminogen

The precursor to PLASMIN.

plas·min·o·gen

(plaz-min'ŏ-jen) [MIM*173350]
A precursor of plasmin; may promote thrombosis.
References in periodicals archive ?
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.
While ligneous conjunctivitis is the best characterized lesion of plasminogen deficiency, hypoplasminogenemia is a multi-systemic disease that can also affect the ears, sinuses, tracheobronchial tree, genitourinary tract, and gingiva.
Hennan et al., "Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization," Journal of Medicinal Chemistry, vol.
The cross-linked [alpha]2AP is fully active and essential for the inhibition of fibrinolysis, particularly of spontaneous fibrinolysis by t-PA-induced plasminogen activation on the fibrin surface [29].
Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.
* The report provides a snapshot of the global therapeutic landscape for Plasminogen Activator Inhibitor-1 (Endothelial Plasminogen Activator Inhibitor or Serpin E1 or PAI-1)
Keywords: Ischemic stroke Reporting time (RT) Therapeutic window Tissue plasminogen activator (TPA).
Tranexamic acid (TA) is an analogue of lysine, (Astedt B-1987)(7) which has powerful antifibrinolytic potency through blocking the lysine-binding sites of plasminogen molecule and is mainly used in bleeding caused by acute or chronic, localized or systemic accentuation of fibrinolysis.
Fibrinolysis is a highly regulated mechanism that, upon deposition of fibrin within the vasculature, converts plasminogen into plasmin, which in turn degrades fibrin (Fig.

Full browser ?